Article
Polymorphisms in OCTN1 and OCTN2 transporters genes are associated with prolonged time to progression in unresectable gastrointestinal stromal tumours treated with imatinib therapy.
Pharmacological research - 1 Feb 2013
Angelini Sabrina, Pantaleo Maria Abbondanza, Ravegnini Gloria, Zenesini Corrado, Cavrini Giulia, Nannini Margherita, Fumagalli Elena, Palassini Elena, Saponara Maristella, Di Battista Monica, Casali Paolo G, Hrelia Patrizia, Cantelli-Forti Giorgio, Biasco Guido
Abstract excerpt
The two basic mainstays of gastrointestinal stromal tumours (GIST) treatment are surgery and imatinib, a selective tyrosine kinase inhibitor that allows achieving a stable or responding disease in about 80% of patients with unresectable/metastatic GIST. Response to imatinib mainly depends from KIT and PDGFRα mutational status. Nevertheless, some patients with a potentially responsive genotype do not respond, and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.